IN2014MN02513A - - Google Patents
Info
- Publication number
- IN2014MN02513A IN2014MN02513A IN2513MUN2014A IN2014MN02513A IN 2014MN02513 A IN2014MN02513 A IN 2014MN02513A IN 2513MUN2014 A IN2513MUN2014 A IN 2513MUN2014A IN 2014MN02513 A IN2014MN02513 A IN 2014MN02513A
- Authority
- IN
- India
- Prior art keywords
- subunits
- mcm
- hmcm6
- hmcm2
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644442P | 2012-05-09 | 2012-05-09 | |
| PCT/US2013/040287 WO2013169989A1 (fr) | 2012-05-09 | 2013-05-09 | Procédé et composés pour l'inhibition du complexe mcm et leur application dans le traitement anticancéreux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02513A true IN2014MN02513A (fr) | 2015-07-17 |
Family
ID=49551267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2513MUN2014 IN2014MN02513A (fr) | 2012-05-09 | 2013-05-09 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11648258B2 (fr) |
| EP (2) | EP2846807B1 (fr) |
| JP (5) | JP2015517500A (fr) |
| CN (2) | CN104736157B (fr) |
| AU (1) | AU2013259486B2 (fr) |
| CA (2) | CA2873283C (fr) |
| ES (1) | ES2949335T3 (fr) |
| IN (1) | IN2014MN02513A (fr) |
| WO (1) | WO2013169989A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019283946B2 (en) * | 2017-05-19 | 2021-05-20 | Enkang Pharmaceuticals (Guangzhou), Ltd. | Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms |
| CN117756875A (zh) | 2017-05-19 | 2024-03-26 | 恩康药业科技（广州）有限公司 | 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用 |
| CN114129582A (zh) * | 2019-03-27 | 2022-03-04 | 天津中医药大学 | 黄夹次乙苷作为抗肿瘤药物的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0592990A (ja) | 1991-08-06 | 1993-04-16 | Taisho Pharmaceut Co Ltd | カルデノライド誘導体 |
| WO2002014343A1 (fr) * | 2000-08-17 | 2002-02-21 | Terness, Peter | Composes analgesiques anti-inflammatoires et immunosuppresseurs |
| US7393950B2 (en) | 2002-08-29 | 2008-07-01 | Hong Kong University Of Science & Technology | Antisense oligonucleotides targeted to human CDC45 |
| US8318922B2 (en) | 2002-08-29 | 2012-11-27 | The Hong Kong Polytechnic University | Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins |
| JP2004131435A (ja) * | 2002-10-11 | 2004-04-30 | Mitsubishi Chemicals Corp | 抗癌剤のスクリーニング方法及び組織の癌化の判定方法 |
| DE10248751A1 (de) | 2002-10-18 | 2004-05-06 | Berdel, Wolfgang E., Prof. Dr.med. | Dyslokalisationsmoleküle und deren Verwendung |
| US20070207120A1 (en) * | 2004-04-14 | 2007-09-06 | Sarah Drayton | Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6 |
| US20090022708A1 (en) | 2004-12-22 | 2009-01-22 | Lobie Peter E | Trefoil Factors and Methods of Treating Proliferation Disorders Using Same |
| EP1787645A1 (fr) | 2005-11-18 | 2007-05-23 | Institut Curie | Nouveau traitement du cancer basé sur la modulation de la voie de la calcineurine et/ou de la calcineurine/NFAT |
| US20090018088A1 (en) * | 2006-10-27 | 2009-01-15 | University Of Louisville Research Foundation | Treating cancer with cardiac glycosides |
| CN101683359B (zh) | 2008-09-28 | 2012-05-09 | 上海秀新臣邦医药科技有限公司 | 一种治疗肿瘤的中药组合物及其制备方法 |
| CN101726577A (zh) * | 2008-10-13 | 2010-06-09 | 中山大学 | 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法 |
| WO2010068247A1 (fr) | 2008-12-10 | 2010-06-17 | Sloan-Kettering Institute For Cancer Research | Cardénolides utilisés pour traiter le cancer de l’œil |
| CN102219821A (zh) | 2011-05-05 | 2011-10-19 | 沈阳药科大学 | 一类强心苷类化合物及其抗肿瘤用途 |
-
2013
- 2013-05-09 EP EP13787939.1A patent/EP2846807B1/fr active Active
- 2013-05-09 CA CA2873283A patent/CA2873283C/fr active Active
- 2013-05-09 WO PCT/US2013/040287 patent/WO2013169989A1/fr active Application Filing
- 2013-05-09 CA CA3111702A patent/CA3111702A1/fr not_active Withdrawn
- 2013-05-09 IN IN2513MUN2014 patent/IN2014MN02513A/en unknown
- 2013-05-09 AU AU2013259486A patent/AU2013259486B2/en active Active
- 2013-05-09 ES ES13787939T patent/ES2949335T3/es active Active
- 2013-05-09 CN CN201380024370.2A patent/CN104736157B/zh active Active
- 2013-05-09 US US14/399,960 patent/US11648258B2/en active Active
- 2013-05-09 JP JP2015511684A patent/JP2015517500A/ja active Pending
- 2013-05-09 EP EP23177484.5A patent/EP4248978A3/fr active Pending
- 2013-05-09 CN CN201910489605.4A patent/CN110412285B/zh active Active
-
2018
- 2018-01-11 JP JP2018002988A patent/JP2018100274A/ja active Pending
-
2019
- 2019-12-27 JP JP2019237597A patent/JP2020073544A/ja active Pending
-
2021
- 2021-09-16 JP JP2021150771A patent/JP2021193132A/ja active Pending
-
2023
- 2023-09-21 JP JP2023154199A patent/JP2024001049A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3111702A1 (fr) | 2013-11-14 |
| CA2873283A1 (fr) | 2013-11-14 |
| CN110412285A (zh) | 2019-11-05 |
| EP2846807C0 (fr) | 2023-06-07 |
| JP2020073544A (ja) | 2020-05-14 |
| AU2013259486B2 (en) | 2019-12-12 |
| CN104736157B (zh) | 2019-06-11 |
| CA2873283C (fr) | 2021-05-04 |
| WO2013169989A1 (fr) | 2013-11-14 |
| JP2018100274A (ja) | 2018-06-28 |
| JP2024001049A (ja) | 2024-01-09 |
| EP4248978A3 (fr) | 2023-11-08 |
| EP2846807B1 (fr) | 2023-06-07 |
| JP2021193132A (ja) | 2021-12-23 |
| US20150099712A1 (en) | 2015-04-09 |
| JP2015517500A (ja) | 2015-06-22 |
| EP2846807A4 (fr) | 2016-07-27 |
| US11648258B2 (en) | 2023-05-16 |
| ES2949335T3 (es) | 2023-09-27 |
| AU2013259486A1 (en) | 2014-12-18 |
| EP2846807A1 (fr) | 2015-03-18 |
| CN110412285B (zh) | 2022-11-15 |
| EP4248978A2 (fr) | 2023-09-27 |
| CN104736157A (zh) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017012947A2 (es) | Inhibidores de tirosina-cinasas | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| CL2018000685A1 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx/ca | |
| MX2020008976A (es) | Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1. | |
| EP3030854A4 (fr) | Procédé et appareil de traitement de boues | |
| PH12014501844B1 (en) | Peptidomimetic macrocycles | |
| TN2013000464A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
| LT3212764T (lt) | Biomasės ir biologinių atliekų perdirbimo būdas | |
| IN2015KN00550A (fr) | ||
| HK1212216A1 (en) | Methods of treating neuroendocrine tumors using wnt pathway-binding agents wnt | |
| CA2864161A1 (fr) | Inhibition du systeme de clivage de la glycine pour le traitement du cancer | |
| MX2017007707A (es) | Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama. | |
| MY180834A (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| EA201690718A1 (ru) | Способ обработки целлюлозосодержащей биомассы | |
| MX351113B (es) | Ensayo para capturar y detectar células circulantes de mieloma múltiple de la sangre. | |
| EA201492187A1 (ru) | Способы лечения солидных опухолей с использованием кофермента q10 | |
| EA201792096A2 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| FR3015970B1 (fr) | Procede de traitement des boues de nature thixotropique et contenant de la matiere organique. | |
| MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
| IN2014MN02513A (fr) | ||
| MY167611A (en) | Method and apparatus for biologically treating organic wastewater | |
| MY167370A (en) | Method for Treating Ballast Water and Device for Treating Ballast Water Used Therefor | |
| GB2514940A (en) | Process and method for the treatment of materials, materials thus obtained and uses of these materials | |
| EP3251123A4 (fr) | Appareils et procédés de traitement de déchets organiques radioactifs | |
| EA201491727A1 (ru) | Способ лечения рака с применением ингибиторов киназы аврора |